A Phase 1, Dose Escalation, and Pharmacokinetic Study of ProMetic Plasminogen Administered as Intravenous Infusion in Adults and Children With Hypoplasminogenemia

Trial Profile

A Phase 1, Dose Escalation, and Pharmacokinetic Study of ProMetic Plasminogen Administered as Intravenous Infusion in Adults and Children With Hypoplasminogenemia

Completed
Phase of Trial: Phase I

Latest Information Update: 17 Feb 2016

At a glance

  • Drugs Plasminogen (Primary)
  • Indications Type I plasminogen deficiency
  • Focus First in man; Pharmacokinetics
  • Sponsors ProMetic Life Sciences
  • Most Recent Events

    • 11 Feb 2016 Study cohort 3 with 12mg/kg (high dose-group of 12 mg/kg Plasminogen (Human) Intravenous) had been removed from treatment table, according to ClinicalTrials.gov record.
    • 11 Feb 2016 Status changed from recruiting to completed, according to ClinicalTrials.gov record.
    • 21 Dec 2015 Planned End Date changed from 1 Aug 2015 to 1 Apr 2017, according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top